Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Thoracic Neoplasms: early-phase trial registry

2 of 5 indexed Thoracic Neoplasms trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Thoracic Neoplasms: 5 US clinical trials tracked, 2 recruiting.

Thoracic Neoplasms is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Syndax Pharmaceuticals, running 2 of these trials.

Enrollment posture brief

Registry condition thoracic-neoplasms

OPEN 2 | RECR 40% | LATE 1 | EARLY 3 | RANK #3391 | SPON 2

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Thoracic Neoplasms (this)40%
Open-enrollment share among volume-matched conditions near Thoracic Neoplasms

Thoracic Neoplasms lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thoracic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thoracic Neoplasms is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Thoracic Neoplasms research.

    Syndax Pharmaceuticals accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Thoracic Neoplasms trials plan to enrol fewer than 100 people.

    Median target enrolment is 39 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Thoracic Neoplasms research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 41

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 4 1

Named interventions

Most-linked intervention names on Thoracic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Entinostat Drug
2 trials
ESB Thoracic Drug
1 trials
Ion Endoluminal System Device
1 trials
Sunitinib Drug
1 trials
External Beam Radiation Therapy Radiation
1 trials
Placebo Drug
1 trials
Pembrolizumab Drug
1 trials

US sites by state

Facility locations filed on Thoracic Neoplasms trials. A trial with sites in several states counts in each.

Texas 3 trials
Wisconsin 1 trials
Utah 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Thoracic Neoplasms page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thoracic Neoplasms condition card totals 5 registered trials; most-linked intervention Entinostat; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.